论文部分内容阅读
目的:了解武汉地区碳青霉烯类药物的应用及趋势。方法:对武汉地区34家医院2007~2014年碳青霉烯类药物的销售金额、用药频度(DDDs)和日均费用(DDC)等进行回顾性统计分析。结果:武汉地区碳青霉烯类总销售金额逐年增长,2014年较2007年增长4倍。比阿培南销售金额增长迅速,自2009年来,临床以美罗培南、亚胺培南/西司他丁、比阿培南三种注射剂为主导,唯一口服品种法罗培南为辅助;各碳青霉烯类药物的DDDs变化规律与销售金额基本一致;所有碳青霉烯类药物的DDC,注射剂型呈逐年下降趋势,降幅以比阿培南最大,但仍居第一位,美罗培南、亚胺培南/西司他丁各年度DDC均超过400元,法罗培南2007~2009年价格波动较大,2009年增加两倍至453元后保持稳定。结论:2011年抗菌药物专项整治措施对抗菌药物遴选起到一定的规范作用;当前该类药物品种合理,但患者经济负担较大。建议继续加强抗菌药物的监管力度,控制药物成本,保障用药合理安全。
Objective: To understand the application and trend of carbapenems in Wuhan. Methods: Retrospective statistical analysis was conducted on the sales amount, DDDs and DDC of carbapenems in 34 hospitals in Wuhan from 2007 to 2014. Results: The total sales of carbapenems in Wuhan increased year by year in 2014, up 4 times from that in 2007. Sales of biapenem have risen rapidly. Since 2009, clinical trials of meropenem, imipenem / cilastatin, and biapenem dominate the oral administration of faropenem; The changes of DDDs of alkene drugs were consistent with the sales value. The DDC and injections of all carbapenems showed a declining trend year by year, which was the largest decline of biapenem but still ranked first. Meropenem, imine Pei Nan / cilastatin DDC each year more than 400 yuan, faropenec 2007-2009 price fluctuations in 2009 doubled to 453 yuan after the steady. Conclusion: The special antimicrobial treatment measures in 2011 play a normative role in the selection of antimicrobial agents. At present, the varieties of such drugs are reasonable, but the patients have a greater financial burden. It is recommended to continue to strengthen the supervision of antimicrobial drugs, control the cost of drugs, and ensure the rational and safe use of drugs.